Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free XAGE Stock Alerts

Longevity Health (XAGE) Competitors

Longevity Health logo
$0.21 -0.01 (-6.22%)
As of 01:07 PM Eastern
Compare

XAGE vs. AEMD, VBIO, BJDX, RBOT, and LYRA

Should you buy Longevity Health stock or one of its competitors? MarketBeat compares Longevity Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Longevity Health include Aethlon Medical (AEMD), Valion Bio, Inc. Common Stock (VBIO), Bluejay Diagnostics (BJDX), Vicarious Surgical (RBOT), and Lyra Therapeutics (LYRA). These companies are all part of the "medical equipment" industry.

How does Longevity Health compare to Aethlon Medical?

Longevity Health (NASDAQ:XAGE) and Aethlon Medical (NASDAQ:AEMD) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

Aethlon Medical has lower revenue, but higher earnings than Longevity Health. Longevity Health is trading at a lower price-to-earnings ratio than Aethlon Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Longevity Health$1.05M0.36-$10.37M-$4.29N/A
Aethlon MedicalN/AN/A-$7.15M-$14.69N/A

In the previous week, Longevity Health had 1 more articles in the media than Aethlon Medical. MarketBeat recorded 1 mentions for Longevity Health and 0 mentions for Aethlon Medical. Longevity Health's average media sentiment score of 0.67 beat Aethlon Medical's score of 0.00 indicating that Longevity Health is being referred to more favorably in the media.

Company Overall Sentiment
Longevity Health Positive
Aethlon Medical Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Longevity Health
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aethlon Medical
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Aethlon Medical has a net margin of 0.00% compared to Longevity Health's net margin of -682.67%. Longevity Health's return on equity of 0.00% beat Aethlon Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Longevity Health-682.67% N/A -261.90%
Aethlon Medical N/A -137.73%-105.87%

Longevity Health has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, Aethlon Medical has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

24.2% of Longevity Health shares are held by institutional investors. Comparatively, 2.0% of Aethlon Medical shares are held by institutional investors. 29.0% of Longevity Health shares are held by insiders. Comparatively, 0.7% of Aethlon Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Longevity Health beats Aethlon Medical on 7 of the 13 factors compared between the two stocks.

How does Longevity Health compare to Valion Bio, Inc. Common Stock?

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and Longevity Health (NASDAQ:XAGE) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Valion Bio, Inc. Common Stock has a beta of 1.82, indicating that its stock price is 82% more volatile than the broader market. Comparatively, Longevity Health has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market.

Valion Bio, Inc. Common Stock has higher earnings, but lower revenue than Longevity Health. Longevity Health is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Valion Bio, Inc. Common Stock$780K1.65-$8.88M-$6.68N/A
Longevity Health$1.05M0.36-$10.37M-$4.29N/A

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to Longevity Health's net margin of -682.67%. Longevity Health's return on equity of 0.00% beat Valion Bio, Inc. Common Stock's return on equity.

Company Net Margins Return on Equity Return on Assets
Valion Bio, Inc. Common StockN/A -138.10% -63.67%
Longevity Health -682.67%N/A -261.90%

4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. Comparatively, 24.2% of Longevity Health shares are owned by institutional investors. 2.2% of Valion Bio, Inc. Common Stock shares are owned by insiders. Comparatively, 29.0% of Longevity Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Valion Bio, Inc. Common Stock
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Longevity Health
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Valion Bio, Inc. Common Stock and Valion Bio, Inc. Common Stock both had 1 articles in the media. Longevity Health's average media sentiment score of 0.67 beat Valion Bio, Inc. Common Stock's score of 0.00 indicating that Longevity Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Valion Bio, Inc. Common Stock
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Longevity Health
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Valion Bio, Inc. Common Stock beats Longevity Health on 7 of the 13 factors compared between the two stocks.

How does Longevity Health compare to Bluejay Diagnostics?

Bluejay Diagnostics (NASDAQ:BJDX) and Longevity Health (NASDAQ:XAGE) are both small-cap medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Bluejay Diagnostics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, Longevity Health has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bluejay Diagnostics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Longevity Health
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

18.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 24.2% of Longevity Health shares are held by institutional investors. 6.1% of Bluejay Diagnostics shares are held by company insiders. Comparatively, 29.0% of Longevity Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Bluejay Diagnostics had 2 more articles in the media than Longevity Health. MarketBeat recorded 3 mentions for Bluejay Diagnostics and 1 mentions for Longevity Health. Bluejay Diagnostics' average media sentiment score of 0.79 beat Longevity Health's score of 0.67 indicating that Bluejay Diagnostics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bluejay Diagnostics
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Longevity Health
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Bluejay Diagnostics has higher earnings, but lower revenue than Longevity Health. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Longevity Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bluejay DiagnosticsN/AN/A-$6.85M-$11.63N/A
Longevity Health$1.05M0.36-$10.37M-$4.29N/A

Bluejay Diagnostics has a net margin of 0.00% compared to Longevity Health's net margin of -682.67%. Longevity Health's return on equity of 0.00% beat Bluejay Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bluejay DiagnosticsN/A -144.27% -115.00%
Longevity Health -682.67%N/A -261.90%

Summary

Bluejay Diagnostics beats Longevity Health on 7 of the 13 factors compared between the two stocks.

How does Longevity Health compare to Vicarious Surgical?

Vicarious Surgical (NYSE:RBOT) and Longevity Health (NASDAQ:XAGE) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

47.3% of Vicarious Surgical shares are held by institutional investors. Comparatively, 24.2% of Longevity Health shares are held by institutional investors. 11.1% of Vicarious Surgical shares are held by company insiders. Comparatively, 29.0% of Longevity Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Vicarious Surgical had 1 more articles in the media than Longevity Health. MarketBeat recorded 2 mentions for Vicarious Surgical and 1 mentions for Longevity Health. Longevity Health's average media sentiment score of 0.67 beat Vicarious Surgical's score of -0.14 indicating that Longevity Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vicarious Surgical
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Longevity Health
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Vicarious Surgical currently has a consensus price target of $7.00, indicating a potential upside of 4,027.36%. Given Vicarious Surgical's stronger consensus rating and higher probable upside, research analysts plainly believe Vicarious Surgical is more favorable than Longevity Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vicarious Surgical
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Longevity Health
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Vicarious Surgical has a net margin of 0.00% compared to Longevity Health's net margin of -682.67%. Longevity Health's return on equity of 0.00% beat Vicarious Surgical's return on equity.

Company Net Margins Return on Equity Return on Assets
Vicarious SurgicalN/A -184.13% -112.50%
Longevity Health -682.67%N/A -261.90%

Vicarious Surgical has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market. Comparatively, Longevity Health has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market.

Longevity Health has higher revenue and earnings than Vicarious Surgical. Longevity Health is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vicarious SurgicalN/AN/A-$63.22M-$6.69N/A
Longevity Health$1.05M0.36-$10.37M-$4.29N/A

Summary

Vicarious Surgical beats Longevity Health on 8 of the 14 factors compared between the two stocks.

How does Longevity Health compare to Lyra Therapeutics?

Longevity Health (NASDAQ:XAGE) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Longevity Health
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Lyra Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

In the previous week, Longevity Health had 1 more articles in the media than Lyra Therapeutics. MarketBeat recorded 1 mentions for Longevity Health and 0 mentions for Lyra Therapeutics. Longevity Health's average media sentiment score of 0.67 beat Lyra Therapeutics' score of 0.00 indicating that Longevity Health is being referred to more favorably in the media.

Company Overall Sentiment
Longevity Health Positive
Lyra Therapeutics Neutral

Longevity Health has a net margin of -682.67% compared to Lyra Therapeutics' net margin of -5,491.17%. Longevity Health's return on equity of 0.00% beat Lyra Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Longevity Health-682.67% N/A -261.90%
Lyra Therapeutics -5,491.17%-1,010.91%-58.92%

Longevity Health has higher revenue and earnings than Lyra Therapeutics. Longevity Health is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Longevity Health$1.05M0.36-$10.37M-$4.29N/A
Lyra Therapeutics$600K1.54-$93.43M-$19.15N/A

Longevity Health has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, Lyra Therapeutics has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

24.2% of Longevity Health shares are owned by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are owned by institutional investors. 29.0% of Longevity Health shares are owned by company insiders. Comparatively, 3.3% of Lyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Longevity Health beats Lyra Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Longevity Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for XAGE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XAGE vs. The Competition

Export
MetricLongevity HealthSurgical, Medical, And Dental Instruments And Supplies IndustryManufacturing SectorNASDAQ Exchange
Market Cap$376K$3.12B$4.44B$12.32B
Dividend YieldN/AN/A40.17%9.67%
P/E Ratio-0.0521.5923.7124.18
Price / Sales0.36262.49176.1496.01
Price / CashN/A8.77163.9759.37
Price / Book-0.035.8313.416.25
Net Income-$10.37M$23.43M$120.21M$331.66M
7 Day Performance-14.85%-2.53%-0.82%-1.10%
1 Month Performance-27.86%-7.75%-1.18%-1.29%
1 Year Performance-94.71%4.15%10.74%18.84%

Longevity Health Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XAGE
Longevity Health
N/A$0.21
-6.2%		N/A-93.8%$376K$1.05MN/A14
AEMD
Aethlon Medical
0.3079 of 5 stars		$0.69
+0.9%		N/A-95.3%$1.64MN/AN/A10
VBIO
Valion Bio, Inc. Common Stock
0.75 of 5 stars		$0.43
-8.8%		N/A-91.1%$1.37M$780KN/A10
BJDX
Bluejay Diagnostics
1.0828 of 5 stars		$1.30
+4.2%		N/A-80.7%$1.35MN/AN/A9
RBOT
Vicarious Surgical
1.6299 of 5 stars		$0.18
+6.1%		$7.00
+3,900.0%		-98.4%$1.25MN/AN/A210

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:XAGE) was last updated on 7/21/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel
Oil is settling in yuan now - here's what that means for gold
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel